Keyword: Newron Pharmaceuticals
The FDA requested the delay after seeing data from studies of glutamate inhibitor evenamide in mice and dogs.
Phase 2a data for Newron's schizophrenia drug evenamide due in March should help the company sign a development partner later this year, says CEO.
Newron Pharmaceuticals has tapped investors for CHF 26.1 million to see it through to data readouts on a couple of key pipeline programs.
Newron Pharmaceuticals has seen a much-needed quick turnaround for its lead Parkinson’s drug as it can now resubmit its candidate in the U.S.--just four months after being blocked by the FDA.